PDF(Pubmed)
Abstract：
UNASSIGNED: Routine use of human papillomavirus (HPV) vaccines is recommended in adolescents under 15 years of age worldwide. Still, effective programs remain suboptimal for several factors, making the WHO strategy to eradicate cervical cancer public health with an uncertain future.
UNASSIGNED: To review the literature on the effectiveness, long-term protection, and safety of HPV vaccination programs and vaccination as adjuvant management. This review aims to describe the current state of vaccination programs and demonstrate the long-term protection and safety of vaccines implemented worldwide targeting adolescent girls, with the most recent published evidence of the three prophylactic HPV vaccines - bivalent (bHPV), quadrivalent (qHPV), and nonavalent (nHPV)-. We mainly focus on publications evaluating efficacy, dosing schemes, and HPV vaccination, as well as studies contributing to the mounting evidence for the real-life effectiveness of prophylactic HPV vaccines from several countries.
UNASSIGNED: Human Papillomavirus vaccination programs have made remarkable strides in preventing HPV-related diseases; countries with robust vaccination efforts have witnessed substantial reductions in HPV-related diseases with a decline in high-grade cervical abnormalities and genital warts (54%-83%). However, global coverage remains uneven, with disparities between high-income (HICs) and low-income countries (LMICs). The long-term efficacy of the available human papillomavirus (HPV) goes up to 9.4 years and continues to be immunogenic and well tolerated with an excellent safety profile.
UNASSIGNED: As these are crucial topics in HPV vaccination, it is essential to establish systems for continued monitoring of vaccine immunogenicity, efficacy, and safety over time.
UNASSIGNED: To review the literature on the effectiveness, long-term protection, and safety of HPV vaccination programs and vaccination as adjuvant management. This review aims to describe the current state of vaccination programs and demonstrate the long-term protection and safety of vaccines implemented worldwide targeting adolescent girls, with the most recent published evidence of the three prophylactic HPV vaccines - bivalent (bHPV), quadrivalent (qHPV), and nonavalent (nHPV)-. We mainly focus on publications evaluating efficacy, dosing schemes, and HPV vaccination, as well as studies contributing to the mounting evidence for the real-life effectiveness of prophylactic HPV vaccines from several countries.
UNASSIGNED: Human Papillomavirus vaccination programs have made remarkable strides in preventing HPV-related diseases; countries with robust vaccination efforts have witnessed substantial reductions in HPV-related diseases with a decline in high-grade cervical abnormalities and genital warts (54%-83%). However, global coverage remains uneven, with disparities between high-income (HICs) and low-income countries (LMICs). The long-term efficacy of the available human papillomavirus (HPV) goes up to 9.4 years and continues to be immunogenic and well tolerated with an excellent safety profile.
UNASSIGNED: As these are crucial topics in HPV vaccination, it is essential to establish systems for continued monitoring of vaccine immunogenicity, efficacy, and safety over time.
摘要：
■建议在全世界15岁以下的青少年中常规使用人乳头瘤病毒（HPV）疫苗。尽管如此，有效的程序在几个因素上仍然是次优的，制定世卫组织根除宫颈癌公共卫生的战略，前景不明朗。
■为了回顾有关有效性的文献，长期保护,以及HPV疫苗接种计划和疫苗接种作为辅助管理的安全性。这篇综述旨在描述疫苗接种计划的现状，并展示全球范围内针对少女实施的疫苗的长期保护和安全性。与最近发表的三种预防性HPV疫苗的证据-二价（bHPV），四价（qHPV），和非单价（nHPV）-。我们主要关注评估疗效的出版物，给药方案，和HPV疫苗接种，以及来自多个国家的预防性HPV疫苗在现实生活中的有效性越来越多的证据的研究。
人乳头瘤病毒疫苗接种计划在预防HPV相关疾病方面取得了显著进展；疫苗接种力度较大的国家已经见证了HPV相关疾病的大幅减少，高度宫颈异常和生殖器疣的减少（54％-83％）。然而,全球覆盖面仍然不均衡，高收入国家(HIC)和低收入国家(LMIC)之间的差距。可用的人乳头瘤病毒（HPV）的长期疗效高达9.4年，并继续具有免疫原性和良好的耐受性，具有出色的安全性。
■由于这些是HPV疫苗接种的重要主题，建立持续监测疫苗免疫原性的系统至关重要，功效,和安全随着时间的推移。
■为了回顾有关有效性的文献，长期保护,以及HPV疫苗接种计划和疫苗接种作为辅助管理的安全性。这篇综述旨在描述疫苗接种计划的现状，并展示全球范围内针对少女实施的疫苗的长期保护和安全性。与最近发表的三种预防性HPV疫苗的证据-二价（bHPV），四价（qHPV），和非单价（nHPV）-。我们主要关注评估疗效的出版物，给药方案，和HPV疫苗接种，以及来自多个国家的预防性HPV疫苗在现实生活中的有效性越来越多的证据的研究。
人乳头瘤病毒疫苗接种计划在预防HPV相关疾病方面取得了显著进展；疫苗接种力度较大的国家已经见证了HPV相关疾病的大幅减少，高度宫颈异常和生殖器疣的减少（54％-83％）。然而,全球覆盖面仍然不均衡，高收入国家(HIC)和低收入国家(LMIC)之间的差距。可用的人乳头瘤病毒（HPV）的长期疗效高达9.4年，并继续具有免疫原性和良好的耐受性，具有出色的安全性。
■由于这些是HPV疫苗接种的重要主题，建立持续监测疫苗免疫原性的系统至关重要，功效,和安全随着时间的推移。
